AI주식인사이트AI Stock Insight
A

프로티아

303360KOSDAQ

73.8 / 100

Reference Date: 2026-09-08

Financial Score28.5 / 40
News Sentiment21.3 / 25
Momentum14.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

ProTia develops, manufactures, and sells in vitro diagnostic medical devices based on immune diagnostic technology, specializing in allergy, food intolerance, and antibiotic susceptibility tests. The company holds over 45% market share domestically and has expanded to 68 countries globally. It continuously innovates through its in-house research institute, earning three Yangsil Awards and four NET technology certifications from the government.

Number of Employees

113people

Average Salary

41.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
14.55Industry Average 15.005.0Point

In line with industry avg

PBR
2.12Industry Average 1.201.0Point

1.8x industry avg (risky)

ROE
15.72Industry Average 8.005.5Point

2.0x industry avg (good)

Debt Ratio
1.33Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20259.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲35.8% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲481.5% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 9.3% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position5.0Point

52w mid range (45%)

Current 5,050Won52-week high 6,55052-week low 3,795
1-month return3.0Point

1m -0.98% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral반기보고서 (2026.06)2026-08-12